Skip to main content

SYSTEMATIC REVIEW article

Front. Nutr.

Sec. Nutrition, Psychology and Brain Health

Volume 12 - 2025 | doi: 10.3389/fnut.2025.1567097

Probiotics as Technological Innovations in Psychiatric Disorders: Patents and Research Reviews

Provisionally accepted
Alyne Almeida De Lima Alyne Almeida De Lima 1Sthefane Silva Santos Sthefane Silva Santos 2Mykaella Andrade De Araújo³ Mykaella Andrade De Araújo³ 3Gabriel Vinderola Gabriel Vinderola 4Cristiane Flora Villarreal Cristiane Flora Villarreal 1,2Max Denisson Maurício Viana Max Denisson Maurício Viana 2*
  • 1 Gonçalo Moniz Institute (IGM), Salvador, Bahia, Brazil
  • 2 Faculty of Pharmacy, Federal University of Bahia (UFBA), Salvador, Bahia, Brazil
  • 3 Federal University of São Francisco Valley, Petrolina, Pernambuco, Brazil
  • 4 National University of Littoral, Santa Fe, Santa Fe, Argentina

The final, formatted version of the article will be published soon.

    Probiotics have shown promising results in treating anxiety and depression by modulating the gutbrain-microbiota axis using probiotics, which has motivated increasing commercial and academic interest in innovations and the probiotic market. This work explored innovation trends in the use of probiotics in the management of anxiety and depression, through a patent search performed in the Espacenet patent database. To expand the discussion, an additional search was performed on ClinicalTrials.gov and ScienceDirect. Recently probiotic innovations developed were deposited as pharmaceutical products (24.1%), functional foods (20.4%), or both (51.8%). Probiotic strains showed anxiolytic, antidepressant or both effects related to one or more mechanisms including modulation of neurotransmitters (61.1%), neuroendocrine mediators (35.2%) or neuroinflammation and oxidative stress (20.3%). The effects mainly were related to strains of the Lactobacillus (48.1%) and Bifidobacterium (38.9%) genera. In an additional search, 1,945 scientific publications and 11 clinical trials were found. Despite the efficacy observed in preclinical and clinical studies, transitioning from academic discoveries to patented innovations is not always straightforward. This review provides evidence for therapeutic applications of novel probiotic technologies in treating psychiatric disorders. It supports further studies exploring their benefits and highlights the need for greater investment in innovation in this area.

    Keywords: antidepressant, anxiolytic, innovation, patent, probiotcs, review

    Received: 06 Feb 2025; Accepted: 07 Apr 2025.

    Copyright: © 2025 Lima, Santos, Araújo³, Vinderola, Villarreal and Viana. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Max Denisson Maurício Viana, Faculty of Pharmacy, Federal University of Bahia (UFBA), Salvador, 40170-115, Bahia, Brazil

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    95% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more